Navigation Links
Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
Date:1/9/2008

ffiliated institutions where he rose to the rank of Professor of Medicine. He has written more than 100 peer- reviewed articles on the treatment of diabetes and has been recognized both locally and nationally for his research in diabetes and growth factors.

Moses received a Bachelor of Science from Duke University and a Medical Doctorate from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, the National Institutes of Health in Bethesda, Md., and Tufts-New England Medical Center in Boston. He is board certified by the American Board of Internal Medicine and has a subspecialty certification in Endocrinology and Metabolism.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
2. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
10. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
11. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a Regional Top ... Top 10 Plastic Surgeon Specialists for Nashville, TN – has ... line includes a Hydration Booster, Retexturing Night Crème, and Anti-aging ... a younger, more radiant appearance while protecting them from the ... is why at Dr. J. J. Wendel Plastic Surgery, we ...
(Date:7/29/2014)... EXpressLO LLC, expert provider of focused ion ... has been granted patent number 8,789,826 by the U.S. ... a unique specimen carrier support grid design described in ... patent for EXpressLO LLC awarded to founder and President, ... patents extend EXpressLO’s portfolio of intellectual property. The EXpressLO™ ...
(Date:7/28/2014)... A new method of building materials using light, developed ... day enable technologies that are often considered the realm ... devices. , Although cloaked starships won,t be a ... have developed for constructing materials with building blocks a ... to control the way that light flies through them, ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Building 'invisible' materials with light 2WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2
... The Netherlands, June 24 The U.S. Department,of Energy,s ... to enable the sale and delivery of an Avantium ... PNNL to,accelerate its catalyst research for infrastructure compatible biofuels ... by Battelle for the U.S. Department of Energy. The,Laboratory ...
... New Report Calls for a Broad Ethics of Emerging Technologies ... of synthetic biology will allow researchers to create biological parts ... to re-engineer existing organisms to perform novel and beneficial tasks. ... to addressing ethical and social issues is called for, especially ...
... WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the company has reached an agreement with the U.S. ... assessment process (SPA) on an amendment to the design ... lead product candidate targeting castrate resistant prostate cancer (CRPC). ...
Cached Biology Technology:Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA 2Does Synthetic Biology Need Synthesized Ethics? 2Does Synthetic Biology Need Synthesized Ethics? 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5
(Date:7/29/2014)... researchers have developed an easier method to create ... work involved in diagnosing diseases. , DNA linked ... strong partnership that can be used in diagnostic ... which tag proteins with DNA can be ... and visualisation of biological material. The method also ...
(Date:7/29/2014)... There,s some good news for parents of preterm babies ... that by the time they become teenagers, the brains of ... born at term. , A study conducted by the University,s ... as the preterm child experiences no brain injury in early ... as good as their term-born peers. , However, the results ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2
... predicted to occur under climate change scenarios has led many ... of wildfires. But a new study in the May issue ... changes in the types of plants growing in an area ... Philip Higuera of Montana State University and his colleagues ...
... Orleans, LA Sharell Bindom, a student in the ... will be awarded the Mead Johnson Research Award in ... the 2009 Experimental Biology Meeting April 18-22 in New ... is intended to recognize the graduate student, resident, or ...
... do all sorts of work, but a fundamental question has ... "There,s no little man sitting there, putting the protein ... biologist at the USC College of Letters, Arts and Sciences. ... tells them where to go in the cell." In ...
Cached Biology News:Plants could override climate change effects on wildfires 2Autopilot guides proteins in brain 2
... yolk protein Vtg in plasma from juvenile or ... for endocrine disrupting chemicals (EDCs) with estrogenic effects ... accepted screening test for the estrogenic effects of ... kit is a double-antibody immunometric (sandwich) EIA for ...
... acid synthetic peptide whose sequence corresponds to residues 115-133 of rat ... terminus): V115 - L - P - S - E ... V - P - N - E - V - L ... been added to facilitate conjugation and is not a part of ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: